September 16, 2015
Mitsubishi Tanabe Pharma Corporation (MTPC) said on September 15 that it has discontinued a Japanese program conducted as part of a global PIII clinical trial for MT-4666, an investigational Alzheimer’s disease treatment, due to safety concerns. In March 2009, MTPC...read more